Nerandomilast is a preferential inhibitor of phosphodiesterase 4B (PDE4B) with antifibrotic and immunomodulatory effects, a ...

The global COPD therapeutics market is on a robust growth trajectory, having achieved a market valuation of USD 12,144.1 million in 2023, and is projected to reach USD 20,035.5 million by 2033, ...